Citi Analysts Think This Robotic AI Stock Can Surge Another 25% From Here

The global robotic surgery market is growing rapidly, driven by technological advancements, particularly in artificial intelligence (AI), which are transforming the healthcare, medical devices, and biotech industries. One standout player, Intuitive Surgical (ISRG), has significantly advanced minimally invasive surgeries across multiple specialties with its flagship product, the da Vinci Surgical System. Founded in 1995, Intuitive Surgical has achieved a remarkable market share of approximately 79.8% in the robotic surgery industry, despite its relatively short time in operation. The company’s first-mover advantage has given it a significant lead in technological development, brand recognition, and clinical adoption.

Investors are drawn to Intuitive’s innovation, revenue growth, and commanding market position. Last year, its stock outperformed the S&P 500 Index ($SPX) with a 57.7% gain compared to the index’s 24% increase. Recently, the company reported impressive fourth-quarter results, leading to a 9.4% rise in its stock this year. Following these results, Citi analyst Joanne Wuensch reaffirmed a “Buy” rating on ISRG and set a high price target of $711. Let’s dive into Intuitive’s earnings and explore why analysts remain so optimistic about the stock.